Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection
Frontiers in Cellular and Infection Microbiology · 06.02.2023 · 13
DOI: 10.3389/fcimb.2023.1129043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 06.02.2023. Verfasst von Si Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, C…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Mycobiome, Clostridioides difficile, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD) and has been reported as a risk factor for poor outcome. However, gut microbiome and mycobiome of IBD patients with CDI have been barely investigated. This study aimed to assess the gut microbiome and mycobiome in IBD patients with CDI.
Methods
We collected fecal samples from patients with active IBD and concomitant CDI (IBD-CDI group, n=25), patients with active IBD and no CDI (IBD-only group, n=51), and healthy subjects (HC, n=40). Patients’ characteristics including demographic data, disease severity, and medication history were collected. Metagenomic sequencing, taxonomic and functional analysis were carried out in the samples.
Results
We found that the bacterial alpha diversity of the IBD-CDI group was decreased. The bacterial and fungal beta diversity variations between IBD patients and HC were significant, regardless of CDI status. But the IBD-CDI group did not significantly cluster separately from the IBD-only group. Several bacterial taxa, including Enterococcus faecium , Ruminococcus gnavus , and Clostridium innocuum were overrepresented in the IBD-CDI group. Furthermore, IBD patients with CDI were distinguished by several fungal taxa, including overrepresentation of Saccharomyces cerevisiae . We also identified functional differences in IBD patients with CDI include enrichment of peptidoglycan biosynthesis. The network analysis indicated specific interactions between microbial markers in IBD-CDI patients.
Conclusion
IBD patients with CDI had pronounced microbial dysbiosis. Gut micro-ecological changes in IBD patients with CDI might provide insight into the pathological process and potential strategies for diagnosis and treatment in this subset of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Microbial Resource and Big Data Center, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Yu, S., Ge, X., Xu, H., Tan, B., Tian, B., Shi, Y., Dai, Y., Li, Y., Hu, S., & Qian, J. (2023). Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1129043
Vancouver
Yu S, Ge X, Xu H, Tan B, Tian B, Shi Y, et al. Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1129043
BibTeX
@article{Yu2023,
author = {Yu, Si and Ge, Xiaomeng and Xu, Hui and Tan, Bei and Tian, Bowen and Shi, Yujie and Dai, Yimin and Li, Yue and Hu, Songnian and Qian, Jiaming},
title = {Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1129043}
}
EUVIMED